10 Health Care Stocks With Whale Alerts In Today's Session
UBS Highlights 30 Stocks Poised for Potential Moves After the Fed's Expected Rate Cut
Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse
S&P 500 Briefly Hits Record High Just Ahead Of Fed Rate Cut, Extends 7-Day Winning Streak: Tuesday's Top 5 Gainers
Moderna Stock Jumps on Canadian Government's Approval of Updated COVID-19 Vaccine
Moderna’s updated Covid-19 vaccine has been approved by the Canadian government.
Biotechnology company Moderna (MRNA.US) announced that after the United States, the Canadian government has approved its updated Covid-19 vaccine. The stock price rose 4.5% to $72.28 on Tuesday afternoon.
Equities Mixed Intraday as Traders Weigh Macro Data, Await Fed Decision
Sector Update: Health Care Stocks Decline in Afternoon Trading
Sector Update: Health Care
Small Caps, Bitcoin Rally As Traders Await Fed Rate Cut; Treasury Yields, US Dollar Tick Up On Strong Retail Sales: What's Driving Markets Tuesday?
Moderna Up Nearly 6%, Best Performer In The S&P 500 And The Nasdaq 100 So Far Today -- Data Talk
Express News | Moderna Shares up 6.7%
Moderna Shares Are Trading Higher Following Reports Suggesting That the Company Received Health Canada Approval for an Updated Covid-19 Vaccine.
Express News | Moderna: Will Promptly Begin Delivery of Updated Covid-19 Vaccines to Public Health Agency of Canada
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
FDA OKs Third Dose for Pfizer and Moderna Covid-19 Vaccines
Moderna (MRNA) Rises Higher Than Market: Key Facts
DeSantis Administration Cautions Against Pfizer, Moderna MRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Moderna Was Most Shorted S&P 500 Healthcare Stock in August for Second Consecutive Month
Goldman Sachs Maintains Moderna(MRNA.US) With Buy Rating, Cuts Target Price to $139
Goldman Sachs analyst Salveen Richter maintains $Moderna(MRNA.US)$ with a buy rating, and adjusts the target price from $178 to $139.According to TipRanks data, the analyst has a success rate of 45.7%